Today's Trend
Legend Biotech Corporation (NASDAQ:LEGN) — recent analyst actions from HC Wainwright are driving intraday moves. The stock is trading higher after the firm reaffirmed a constructive view, but multiple downward EPS revisions for 2026–2027 cap some upside as investors weigh near-term softness vs. a $50 price target.
- HC Wainwright reiterated a "Buy" rating and maintained a $50.00 price target on LEGN, a bullish endorsement that supports upside expectations. MarketBeat LEGN
- The firm raised its Q1 2026 EPS view to $0.00 from ($0.04), signaling a modest near-term improvement in profitability expectations. MarketBeat LEGN
- Coverage commentary on Legend alongside peers appeared in The Globe and Mail — general analyst insight rather than company-specific catalysts. Analysts Offer Insights on Healthcare Companies
- HC Wainwright sharply cut its FY2027 EPS forecast to $1.14 from $2.28, a large downward revision that reduces long-term earnings upside and could pressure the multiple investors are willing to pay. MarketBeat LEGN
- The firm also reduced FY2026 EPS to $0.21 from $0.42, signaling weaker near-term profitability than previously expected. MarketBeat LEGN
- Several quarterly estimates for 2026 were trimmed (Q2 to $0.03 from $0.06; Q3 to $0.07 from $0.14; Q4 to $0.11 from $0.26), suggesting HC Wainwright sees slower ramp in quarterly results — a near-term headwind for the shares. MarketBeat LEGN
Bottom line for investors: the maintained Buy rating and $50 target are supportive and likely why shares are trading up, but the string of lowered 2026–2027 EPS estimates introduces risk if Legend's revenue/profit ramp proves slower than expected. Monitor upcoming quarterly results and management commentary for confirmation of the growth trajectory that underpins the $50 target.